Article

Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial

2022-04-19

Abstract excerpt

<h4>Importance</h4> The performance of immunoassays for determining past SARS-CoV-2 infection, which were developed in unvaccinated individuals, has not been assessed in vaccinated individuals. <h4>Objective</h4> To evaluate anti-nucleocapsid antibody (anti-N Ab) seropositivity in mRNA-1273 vaccine efficacy trial participants after SARS-CoV-2 infection during the trial’s blinded phase. <h4>Design</h4> Nested analy...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4d58856e-9817-54e6-b072-6201505b93e7
DOI: 10.1101/2022.04.18.22271936

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trialDOI 10.1101/2022.04.18.22271936Read

Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care settingSemantic proximity Read

Prevention of COVID-19 by mRNA-based vaccines within the general population of CaliforniaSemantic proximity Read

Real-world effectiveness and non-inferiority evaluation and comparison of mRNA- and protein-based COVID-19 vaccines: a randomized study protocol (BEEHIVE)Semantic proximity Read

Effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe COVID-19 outcomes in Ontario, Canada: a test-negative design studySemantic proximity Read

Expert Review of Global Real-World Vaccine Effectiveness Against SARS-CoV-2Semantic proximity Read

Seroincidence of SARS-CoV-2 infection prior to and during the rollout of vaccines in a community-based prospective cohort of U.S. adultsSemantic proximity Read

SARS-CoV-2 Breakthrough Infections in Fully Vaccinated IndividualsSemantic proximity Read

Titers and capacity of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: a single-blinded, randomized clinical trialSemantic proximity Read

Determinants of early antibody responses to COVID-19 mRNA vaccines in exposed and naive healthcare workersSemantic proximity Read

Demographic and Clinical Factors Associated With Anti–SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine DosesSemantic proximity Read

Comparative effectiveness of mRNA-1273 versus protein-based NVX-CoV2705 vaccination on COVID-19-related outcomes among US insured adults during 2024–2025: a retrospective matched cohort studySemantic proximity Read

STUDY PROTOCOL A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): A trial conducted within the VACCELERATE networkSemantic proximity Read